Another reason for higher IO efficacy in BRAF-mutant NSCLC, as opposed to EGFR or ALK, is the higher tumor mutational burden (TMB) and more frequent smoking status, as almost half of the BRAF-mutant NSCLC patients are found to be smokers [60]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.